Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Bovine, Human, Mouse, Primate, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to the carboxy terminus of human c-Cbl|
|Purification||Antigen affinity chromatography|
|Storage buffer||0.01M HEPES, pH 7.5, with 0.15M NaCl, 100µg/ml BSA, 50% glycerol|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
It is not recommended to aliquot this antibody.
The cbl oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Cas-Br-M (murine) ecotropic retroviral transforming sequence; Casitas B-lineage lymphoma; casitas B-lineage lymphoma proto-oncogene; Cbl proto-oncogene, E3 ubiquitin protein ligase; E3 ubiquitin-protein ligase CBL; fragile site, folic acid type, rare, fra(11)(q23.3); oncogene CBL2; proto-oncogene c-CBL; RING finger protein 55; signal transduction protein CBL
4732447J05Rik; C-CBL; CBL; Cbl-2; CBL2; FRA11B; NSLL; RGD1561386; RNF55